APO Research
Talk to an analyst

APO RESEARCH · REPORT

First in Class (FIC) Antibody Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global First in Class (FIC) Antibody Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

23 December 2025199 pages

Choose your research edition.

Industry ResearchFirst in Class (FIC) Antibody Drugs Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal First in Class (FIC) Antibody Drugs Industry Growth and Trends Forecast to 2032125 pages · $3,450 USDMarket StructureGlobal First in Class (FIC) Antibody Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal First in Class (FIC) Antibody Drugs Market Outlook and Growth Opportunities 2026215 pages · $4,250 USDMarket Analysis & ForecastGlobal First in Class (FIC) Antibody Drugs Market Analysis and Forecast 2026-2032216 pages · $4,950 USD

Market perspective

The global First in Class (FIC) Antibody Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for First in Class (FIC) Antibody Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for First in Class (FIC) Antibody Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for First in Class (FIC) Antibody Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for First in Class (FIC) Antibody Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of First in Class (FIC) Antibody Drugs include Suzhou Zejing Biopharmaceutical, Foreseen Biotechnology, Shenzhen Yipusheng, Suzhou Yilian Biopharmaceutical, Beijing Hotgen Biotech, Johnson & Johnson, Lixin Pharmaceutical Technology, Akeso, Inc and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global First in Class (FIC) Antibody Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of First in Class (FIC) Antibody Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents First in Class (FIC) Antibody Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the First in Class (FIC) Antibody Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

First in Class (FIC) Antibody Drugs Segment by Company

Suzhou Zejing Biopharmaceutical

Foreseen Biotechnology

Shenzhen Yipusheng

Suzhou Yilian Biopharmaceutical

Beijing Hotgen Biotech

Johnson & Johnson

Lixin Pharmaceutical Technology

Akeso, Inc

Pfizer

Jiangsu Hengrui Medicine

GSK

Shanghai Henlius Biotech, Inc.

Dizal Pharma

AstraZeneca

Vertex Pharmaceuticals

Truqap

Telix

Talvey

Skyclary

Regeneron Pharmaceuticals

Pumis Biotechnology (BioNTech)

Ogsiveo

Merus

Lytgobi

Litfulo

Immatics

Fabhalta

Bicara Therapeutics

Bayer Corporation

Arvinas

First in Class (FIC) Antibody Drugs Segment by Type

Large Molecule FIC Drugs

Small Molecule FIC Drugs

First in Class (FIC) Antibody Drugs Segment by Application

Tumors and Cancers

Nervous System Diseases

Others

First in Class (FIC) Antibody Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global First in Class (FIC) Antibody Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of First in Class (FIC) Antibody Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of First in Class (FIC) Antibody Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the First in Class (FIC) Antibody Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of First in Class (FIC) Antibody Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of First in Class (FIC) Antibody Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of First in Class (FIC) Antibody Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. First in Class (FIC) Antibody Drugs Industry Trends Table 2. First in Class (FIC) Antibody Drugs Industry Drivers Table 3. First in Class (FIC) Antibody Drugs Industry Opportunities and Challenges Table 4. First in Class (FIC) Antibody Drugs Industry Restraints Table 5. Global First in Class (FIC) Antibody Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global First in Class (FIC) Antibody Drugs Sales by Manufacturers (k units) & (2021-2026) Table 8. Global First in Class (FIC) Antibody Drugs Sales Market Share by Manufacturers Table 9. Global First in Class (FIC) Antibody Drugs Average Sales Price (USD/unit) of Manufacturers (2021-2026) Table 10. Global First in Class (FIC) Antibody Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global First in Class (FIC) Antibody Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global First in Class (FIC) Antibody Drugs Manufacturers, Product Type & Application Table 13. Global First in Class (FIC) Antibody Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global First in Class (FIC) Antibody Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Large Molecule FIC Drugs Table 17. Major Manufacturers of Small Molecule FIC Drugs Table 18. Global First in Class (FIC) Antibody Drugs Sales by Type 2021 VS 2025 VS 2032 (k units) Table 19. Global First in Class (FIC) Antibody Drugs Sales by Type (2021-2026) & (k units) Table 20. Global First in Class (FIC) Antibody Drugs Sales by Type (2027-2032) & (k units) Table 21. Global First in Class (FIC) Antibody Drugs Sales Market Share by Type (2021-2026) Table 22. Global First in Class (FIC) Antibody Drugs Sales Market Share by Type (2027-2032) Table 23. Global First in Class (FIC) Antibody Drugs Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global First in Class (FIC) Antibody Drugs Revenue by Type (2021-2026) & (k units) Table 25. Global First in Class (FIC) Antibody Drugs Revenue by Type (2027-2032) & (k units) Table 26. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Type (2021-2026) Table 27. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Tumors and Cancers Table 29. Major Manufacturers of Nervous System Diseases Table 30. Major Manufacturers of Others Table 31. Global First in Class (FIC) Antibody Drugs Sales by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global First in Class (FIC) Antibody Drugs Sales by Application (2021-2026) & (k units) Table 33. Global First in Class (FIC) Antibody Drugs Sales by Application (2027-2032) & (k units) Table 34. Global First in Class (FIC) Antibody Drugs Sales Market Share by Application (2021-2026) Table 35. Global First in Class (FIC) Antibody Drugs Sales Market Share by Application (2027-2032) Table 36. Global First in Class (FIC) Antibody Drugs Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global First in Class (FIC) Antibody Drugs Revenue by Application (2021-2026) & (k units) Table 38. Global First in Class (FIC) Antibody Drugs Revenue by Application (2027-2032) & (k units) Table 39. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Application (2021-2026) Table 40. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Application (2027-2032) Table 41. Global First in Class (FIC) Antibody Drugs Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global First in Class (FIC) Antibody Drugs Sales by Region (2021-2026) & (k units) Table 43. Global First in Class (FIC) Antibody Drugs Sales Market Share by Region (2021-2026) Table 44. Global First in Class (FIC) Antibody Drugs Sales Forecasted by Region (2027-2032) & (k units) Table 45. Global First in Class (FIC) Antibody Drugs Sales Forecasted Market Share by Region (2027-2032) Table 46. North America First in Class (FIC) Antibody Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 47. North America First in Class (FIC) Antibody Drugs Sales by Country (2021-2026) & (k units) Table 48. North America First in Class (FIC) Antibody Drugs Sales by Country (2027-2032) & (k units) Table 49. Europe First in Class (FIC) Antibody Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 50. Europe First in Class (FIC) Antibody Drugs Sales by Country (2021-2026) & (k units) Table 51. Europe First in Class (FIC) Antibody Drugs Sales by Country (2027-2032) & (k units) Table 52. Asia Pacific First in Class (FIC) Antibody Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. Asia Pacific First in Class (FIC) Antibody Drugs Sales by Country (2021-2026) & (k units) Table 54. Asia Pacific First in Class (FIC) Antibody Drugs Sales by Country (2027-2032) & (k units) Table 55. South America, Middle East and Africa First in Class (FIC) Antibody Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. South America, Middle East and Africa First in Class (FIC) Antibody Drugs Sales by Country (2021-2026) & (k units) Table 57. South America, Middle East and Africa First in Class (FIC) Antibody Drugs Sales by Country (2027-2032) & (k units) Table 58. Global First in Class (FIC) Antibody Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global First in Class (FIC) Antibody Drugs Revenue by Region (2021-2026) & (US$ Million) Table 60. Global First in Class (FIC) Antibody Drugs Revenue by Region (2027-2032) & (US$ Million) Table 61. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Region (2021-2026) Table 62. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Region (2027-2032) Table 63. Suzhou Zejing Biopharmaceutical Company Information Table 64. Suzhou Zejing Biopharmaceutical Business Overview Table 65. Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drugs Product Portfolio Table 67. Suzhou Zejing Biopharmaceutical Recent Development Table 68. Foreseen Biotechnology Company Information Table 69. Foreseen Biotechnology Business Overview Table 70. Foreseen Biotechnology First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Foreseen Biotechnology First in Class (FIC) Antibody Drugs Product Portfolio Table 72. Foreseen Biotechnology Recent Development Table 73. Shenzhen Yipusheng Company Information Table 74. Shenzhen Yipusheng Business Overview Table 75. Shenzhen Yipusheng First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Shenzhen Yipusheng First in Class (FIC) Antibody Drugs Product Portfolio Table 77. Shenzhen Yipusheng Recent Development Table 78. Suzhou Yilian Biopharmaceutical Company Information Table 79. Suzhou Yilian Biopharmaceutical Business Overview Table 80. Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drugs Product Portfolio Table 82. Suzhou Yilian Biopharmaceutical Recent Development Table 83. Beijing Hotgen Biotech Company Information Table 84. Beijing Hotgen Biotech Business Overview Table 85. Beijing Hotgen Biotech First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Beijing Hotgen Biotech First in Class (FIC) Antibody Drugs Product Portfolio Table 87. Beijing Hotgen Biotech Recent Development Table 88. Johnson & Johnson Company Information Table 89. Johnson & Johnson Business Overview Table 90. Johnson & Johnson First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Johnson & Johnson First in Class (FIC) Antibody Drugs Product Portfolio Table 92. Johnson & Johnson Recent Development Table 93. Lixin Pharmaceutical Technology Company Information Table 94. Lixin Pharmaceutical Technology Business Overview Table 95. Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drugs Product Portfolio Table 97. Lixin Pharmaceutical Technology Recent Development Table 98. Akeso, Inc Company Information Table 99. Akeso, Inc Business Overview Table 100. Akeso, Inc First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Akeso, Inc First in Class (FIC) Antibody Drugs Product Portfolio Table 102. Akeso, Inc Recent Development Table 103. Pfizer Company Information Table 104. Pfizer Business Overview Table 105. Pfizer First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Pfizer First in Class (FIC) Antibody Drugs Product Portfolio Table 107. Pfizer Recent Development Table 108. Jiangsu Hengrui Medicine Company Information Table 109. Jiangsu Hengrui Medicine Business Overview Table 110. Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drugs Product Portfolio Table 112. Jiangsu Hengrui Medicine Recent Development Table 113. GSK Company Information Table 114. GSK Business Overview Table 115. GSK First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. GSK First in Class (FIC) Antibody Drugs Product Portfolio Table 117. GSK Recent Development Table 118. Shanghai Henlius Biotech, Inc. Company Information Table 119. Shanghai Henlius Biotech, Inc. Business Overview Table 120. Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drugs Product Portfolio Table 122. Shanghai Henlius Biotech, Inc. Recent Development Table 123. Dizal Pharma Company Information Table 124. Dizal Pharma Business Overview Table 125. Dizal Pharma First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Dizal Pharma First in Class (FIC) Antibody Drugs Product Portfolio Table 127. Dizal Pharma Recent Development Table 128. AstraZeneca Company Information Table 129. AstraZeneca Business Overview Table 130. AstraZeneca First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. AstraZeneca First in Class (FIC) Antibody Drugs Product Portfolio Table 132. AstraZeneca Recent Development Table 133. Vertex Pharmaceuticals Company Information Table 134. Vertex Pharmaceuticals Business Overview Table 135. Vertex Pharmaceuticals First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Vertex Pharmaceuticals First in Class (FIC) Antibody Drugs Product Portfolio Table 137. Vertex Pharmaceuticals Recent Development Table 138. Truqap Company Information Table 139. Truqap Business Overview Table 140. Truqap First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Truqap First in Class (FIC) Antibody Drugs Product Portfolio Table 142. Truqap Recent Development Table 143. Telix Company Information Table 144. Telix Business Overview Table 145. Telix First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 146. Telix First in Class (FIC) Antibody Drugs Product Portfolio Table 147. Telix Recent Development Table 148. Talvey Company Information Table 149. Talvey Business Overview Table 150. Talvey First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 151. Talvey First in Class (FIC) Antibody Drugs Product Portfolio Table 152. Talvey Recent Development Table 153. Skyclary Company Information Table 154. Skyclary Business Overview Table 155. Skyclary First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 156. Skyclary First in Class (FIC) Antibody Drugs Product Portfolio Table 157. Skyclary Recent Development Table 158. Regeneron Pharmaceuticals Company Information Table 159. Regeneron Pharmaceuticals Business Overview Table 160. Regeneron Pharmaceuticals First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 161. Regeneron Pharmaceuticals First in Class (FIC) Antibody Drugs Product Portfolio Table 162. Regeneron Pharmaceuticals Recent Development Table 163. Pumis Biotechnology (BioNTech) Company Information Table 164. Pumis Biotechnology (BioNTech) Business Overview Table 165. Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 166. Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drugs Product Portfolio Table 167. Pumis Biotechnology (BioNTech) Recent Development Table 168. Ogsiveo Company Information Table 169. Ogsiveo Business Overview Table 170. Ogsiveo First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 171. Ogsiveo First in Class (FIC) Antibody Drugs Product Portfolio Table 172. Ogsiveo Recent Development Table 173. Merus Company Information Table 174. Merus Business Overview Table 175. Merus First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 176. Merus First in Class (FIC) Antibody Drugs Product Portfolio Table 177. Merus Recent Development Table 178. Lytgobi Company Information Table 179. Lytgobi Business Overview Table 180. Lytgobi First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 181. Lytgobi First in Class (FIC) Antibody Drugs Product Portfolio Table 182. Lytgobi Recent Development Table 183. Litfulo Company Information Table 184. Litfulo Business Overview Table 185. Litfulo First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 186. Litfulo First in Class (FIC) Antibody Drugs Product Portfolio Table 187. Litfulo Recent Development Table 188. Immatics Company Information Table 189. Immatics Business Overview Table 190. Immatics First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 191. Immatics First in Class (FIC) Antibody Drugs Product Portfolio Table 192. Immatics Recent Development Table 193. Fabhalta Company Information Table 194. Fabhalta Business Overview Table 195. Fabhalta First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 196. Fabhalta First in Class (FIC) Antibody Drugs Product Portfolio Table 197. Fabhalta Recent Development Table 198. Bicara Therapeutics Company Information Table 199. Bicara Therapeutics Business Overview Table 200. Bicara Therapeutics First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 201. Bicara Therapeutics First in Class (FIC) Antibody Drugs Product Portfolio Table 202. Bicara Therapeutics Recent Development Table 203. Bayer Corporation Company Information Table 204. Bayer Corporation Business Overview Table 205. Bayer Corporation First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 206. Bayer Corporation First in Class (FIC) Antibody Drugs Product Portfolio Table 207. Bayer Corporation Recent Development Table 208. Arvinas Company Information Table 209. Arvinas Business Overview Table 210. Arvinas First in Class (FIC) Antibody Drugs Sales (k units), Price (USD/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 211. Arvinas First in Class (FIC) Antibody Drugs Product Portfolio Table 212. Arvinas Recent Development Table 213. Key Raw Materials Table 214. Raw Materials Key Suppliers Table 215. First in Class (FIC) Antibody Drugs Distributors List Table 216. First in Class (FIC) Antibody Drugs Customers List Table 217. Research Programs/Design for This Report Table 218. Authors List of This Report Table 219. Secondary Sources Table 220. Primary Sources List of Figures Figure 1. First in Class (FIC) Antibody Drugs Product Image Figure 2. Global First in Class (FIC) Antibody Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global First in Class (FIC) Antibody Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global First in Class (FIC) Antibody Drugs Sales (2021-2032) & (k units) Figure 5. Global First in Class (FIC) Antibody Drugs Average Price (USD/unit) & (2021-2032) Figure 6. Global Top 5 and 10 First in Class (FIC) Antibody Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Large Molecule FIC Drugs Image Figure 9. Small Molecule FIC Drugs Image Figure 10. Global First in Class (FIC) Antibody Drugs Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 11. Global First in Class (FIC) Antibody Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global First in Class (FIC) Antibody Drugs Sales Market Share by Type (2021-2032) Figure 13. Global First in Class (FIC) Antibody Drugs Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global First in Class (FIC) Antibody Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Type (2021-2032) Figure 16. Tumors and Cancers Image Figure 17. Nervous System Diseases Image Figure 18. Others Image Figure 19. Global First in Class (FIC) Antibody Drugs Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global First in Class (FIC) Antibody Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global First in Class (FIC) Antibody Drugs Sales Market Share by Application (2021-2032) Figure 22. Global First in Class (FIC) Antibody Drugs Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global First in Class (FIC) Antibody Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Application (2021-2032) Figure 25. North America First in Class (FIC) Antibody Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 26. North America First in Class (FIC) Antibody Drugs Sales Market Share by Country (2021-2032) Figure 27. U.S. First in Class (FIC) Antibody Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 28. Canada First in Class (FIC) Antibody Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 29. Mexico First in Class (FIC) Antibody Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 30. Europe First in Class (FIC) Antibody Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe First in Class (FIC) Antibody Drugs Sales Market Share by Country (2021-2032) Figure 32. Germany First in Class (FIC) Antibody Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 33. France First in Class (FIC) Antibody Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 34. U.K. First in Class (FIC) Antibody Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 35. Italy First in Class (FIC) Antibody Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 36. Netherlands First in Class (FIC) Antibody Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 37. Asia Pacific First in Class (FIC) Antibody Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific First in Class (FIC) Antibody Drugs Sales Market Share by Country (2021-2032) Figure 39. China First in Class (FIC) Antibody Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 40. Japan First in Class (FIC) Antibody Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 41. South Korea First in Class (FIC) Antibody Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 42. Southeast Asia First in Class (FIC) Antibody Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 43. India First in Class (FIC) Antibody Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 44. Australia First in Class (FIC) Antibody Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 45. South America, Middle East and Africa First in Class (FIC) Antibody Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa First in Class (FIC) Antibody Drugs Sales Market Share by Country (2021-2032) Figure 47. Brazil First in Class (FIC) Antibody Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 48. South Africa First in Class (FIC) Antibody Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 49. Saudi Arabia First in Class (FIC) Antibody Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 50. Turkey First in Class (FIC) Antibody Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 51. Argentina First in Class (FIC) Antibody Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 52. UAE First in Class (FIC) Antibody Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 53. Egypt First in Class (FIC) Antibody Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 54. Chile First in Class (FIC) Antibody Drugs Sales and Growth Rate (2021-2032) & (k units) Figure 55. Global First in Class (FIC) Antibody Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global First in Class (FIC) Antibody Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Figure 58. North America First in Class (FIC) Antibody Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Figure 60. Europe First in Class (FIC) Antibody Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific First in Class (FIC) Antibody Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa First in Class (FIC) Antibody Drugs Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa First in Class (FIC) Antibody Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. First in Class (FIC) Antibody Drugs Value Chain Figure 66. Manufacturing Cost Structure Figure 67. First in Class (FIC) Antibody Drugs Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Large Molecule FIC Drugs
  • Small Molecule FIC Drugs
Applications
  • Tumors and Cancers
  • Nervous System Diseases
  • Others
Companies covered
  • Suzhou Zejing Biopharmaceutical
  • Foreseen Biotechnology
  • Shenzhen Yipusheng
  • Suzhou Yilian Biopharmaceutical
  • Beijing Hotgen Biotech
  • Johnson & Johnson
  • Lixin Pharmaceutical Technology
  • Akeso, Inc
  • Pfizer
  • Jiangsu Hengrui Medicine
  • GSK
  • Shanghai Henlius Biotech, Inc.
  • Dizal Pharma
  • AstraZeneca
  • Vertex Pharmaceuticals
  • Truqap
  • Telix
  • Talvey
  • Skyclary
  • Regeneron Pharmaceuticals
  • Pumis Biotechnology (BioNTech)
  • Ogsiveo
  • Merus
  • Lytgobi
  • Litfulo
  • Immatics
  • Fabhalta
  • Bicara Therapeutics
  • Bayer Corporation
  • Arvinas

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global First in Class (FIC) Antibody Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global First in Class (FIC) Antibody Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global First in Class (FIC) Antibody Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global First in Class (FIC) Antibody Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global First in Class (FIC) Antibody Drugs Market Dynamics
  1. 2.1 First in Class (FIC) Antibody Drugs Industry Trends
  2. 2.2 First in Class (FIC) Antibody Drugs Industry Drivers
  3. 2.3 First in Class (FIC) Antibody Drugs Industry Opportunities and Challenges
  4. 2.4 First in Class (FIC) Antibody Drugs Industry Restraints
3 First in Class (FIC) Antibody Drugs Market by Manufacturers
  1. 3.1 Global First in Class (FIC) Antibody Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global First in Class (FIC) Antibody Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global First in Class (FIC) Antibody Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global First in Class (FIC) Antibody Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global First in Class (FIC) Antibody Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global First in Class (FIC) Antibody Drugs Manufacturers, Product Type & Application
  7. 3.7 Global First in Class (FIC) Antibody Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global First in Class (FIC) Antibody Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 First in Class (FIC) Antibody Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 First in Class (FIC) Antibody Drugs Tier 1, Tier 2, and Tier 3
4 First in Class (FIC) Antibody Drugs Market by Type
  1. 4.1 First in Class (FIC) Antibody Drugs Type Introduction
  2. 4.1.1 Large Molecule FIC Drugs
  3. 4.1.2 Small Molecule FIC Drugs
  4. 4.2 Global First in Class (FIC) Antibody Drugs Sales by Type
  5. 4.2.1 Global First in Class (FIC) Antibody Drugs Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global First in Class (FIC) Antibody Drugs Sales by Type (2021-2032)
  7. 4.2.3 Global First in Class (FIC) Antibody Drugs Sales Market Share by Type (2021-2032)
  8. 4.3 Global First in Class (FIC) Antibody Drugs Revenue by Type
  9. 4.3.1 Global First in Class (FIC) Antibody Drugs Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global First in Class (FIC) Antibody Drugs Revenue by Type (2021-2032)
  11. 4.3.3 Global First in Class (FIC) Antibody Drugs Revenue Market Share by Type (2021-2032)
5 First in Class (FIC) Antibody Drugs Market by Application
  1. 5.1 First in Class (FIC) Antibody Drugs Application Introduction
  2. 5.1.1 Tumors and Cancers
  3. 5.1.2 Nervous System Diseases
  4. 5.1.3 Others
  5. 5.2 Global First in Class (FIC) Antibody Drugs Sales by Application
  6. 5.2.1 Global First in Class (FIC) Antibody Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global First in Class (FIC) Antibody Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global First in Class (FIC) Antibody Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global First in Class (FIC) Antibody Drugs Revenue by Application
  10. 5.3.1 Global First in Class (FIC) Antibody Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global First in Class (FIC) Antibody Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global First in Class (FIC) Antibody Drugs Revenue Market Share by Application (2021-2032)
6 Global First in Class (FIC) Antibody Drugs Sales by Region
  1. 6.1 Global First in Class (FIC) Antibody Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global First in Class (FIC) Antibody Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global First in Class (FIC) Antibody Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global First in Class (FIC) Antibody Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America First in Class (FIC) Antibody Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America First in Class (FIC) Antibody Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe First in Class (FIC) Antibody Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe First in Class (FIC) Antibody Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific First in Class (FIC) Antibody Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific First in Class (FIC) Antibody Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa First in Class (FIC) Antibody Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa First in Class (FIC) Antibody Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global First in Class (FIC) Antibody Drugs Revenue by Region
  1. 7.1 Global First in Class (FIC) Antibody Drugs Revenue by Region
  2. 7.1.1 Global First in Class (FIC) Antibody Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global First in Class (FIC) Antibody Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global First in Class (FIC) Antibody Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global First in Class (FIC) Antibody Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America First in Class (FIC) Antibody Drugs Revenue (2021-2032)
  8. 7.2.2 North America First in Class (FIC) Antibody Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe First in Class (FIC) Antibody Drugs Revenue (2021-2032)
  11. 7.3.2 Europe First in Class (FIC) Antibody Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific First in Class (FIC) Antibody Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific First in Class (FIC) Antibody Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa First in Class (FIC) Antibody Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa First in Class (FIC) Antibody Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Suzhou Zejing Biopharmaceutical
  2. 8.1.1 Suzhou Zejing Biopharmaceutical Company Information
  3. 8.1.2 Suzhou Zejing Biopharmaceutical Business Overview
  4. 8.1.3 Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drugs Product Portfolio
  6. 8.1.5 Suzhou Zejing Biopharmaceutical Recent Developments
  7. 8.2 Foreseen Biotechnology
  8. 8.2.1 Foreseen Biotechnology Company Information
  9. 8.2.2 Foreseen Biotechnology Business Overview
  10. 8.2.3 Foreseen Biotechnology First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Foreseen Biotechnology First in Class (FIC) Antibody Drugs Product Portfolio
  12. 8.2.5 Foreseen Biotechnology Recent Developments
  13. 8.3 Shenzhen Yipusheng
  14. 8.3.1 Shenzhen Yipusheng Company Information
  15. 8.3.2 Shenzhen Yipusheng Business Overview
  16. 8.3.3 Shenzhen Yipusheng First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shenzhen Yipusheng First in Class (FIC) Antibody Drugs Product Portfolio
  18. 8.3.5 Shenzhen Yipusheng Recent Developments
  19. 8.4 Suzhou Yilian Biopharmaceutical
  20. 8.4.1 Suzhou Yilian Biopharmaceutical Company Information
  21. 8.4.2 Suzhou Yilian Biopharmaceutical Business Overview
  22. 8.4.3 Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drugs Product Portfolio
  24. 8.4.5 Suzhou Yilian Biopharmaceutical Recent Developments
  25. 8.5 Beijing Hotgen Biotech
  26. 8.5.1 Beijing Hotgen Biotech Company Information
  27. 8.5.2 Beijing Hotgen Biotech Business Overview
  28. 8.5.3 Beijing Hotgen Biotech First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Beijing Hotgen Biotech First in Class (FIC) Antibody Drugs Product Portfolio
  30. 8.5.5 Beijing Hotgen Biotech Recent Developments
  31. 8.6 Johnson & Johnson
  32. 8.6.1 Johnson & Johnson Company Information
  33. 8.6.2 Johnson & Johnson Business Overview
  34. 8.6.3 Johnson & Johnson First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Johnson & Johnson First in Class (FIC) Antibody Drugs Product Portfolio
  36. 8.6.5 Johnson & Johnson Recent Developments
  37. 8.7 Lixin Pharmaceutical Technology
  38. 8.7.1 Lixin Pharmaceutical Technology Company Information
  39. 8.7.2 Lixin Pharmaceutical Technology Business Overview
  40. 8.7.3 Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drugs Product Portfolio
  42. 8.7.5 Lixin Pharmaceutical Technology Recent Developments
  43. 8.8 Akeso, Inc
  44. 8.8.1 Akeso, Inc Company Information
  45. 8.8.2 Akeso, Inc Business Overview
  46. 8.8.3 Akeso, Inc First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Akeso, Inc First in Class (FIC) Antibody Drugs Product Portfolio
  48. 8.8.5 Akeso, Inc Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer First in Class (FIC) Antibody Drugs Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 Jiangsu Hengrui Medicine
  56. 8.10.1 Jiangsu Hengrui Medicine Company Information
  57. 8.10.2 Jiangsu Hengrui Medicine Business Overview
  58. 8.10.3 Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drugs Product Portfolio
  60. 8.10.5 Jiangsu Hengrui Medicine Recent Developments
  61. 8.11 GSK
  62. 8.11.1 GSK Company Information
  63. 8.11.2 GSK Business Overview
  64. 8.11.3 GSK First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 GSK First in Class (FIC) Antibody Drugs Product Portfolio
  66. 8.11.5 GSK Recent Developments
  67. 8.12 Shanghai Henlius Biotech, Inc.
  68. 8.12.1 Shanghai Henlius Biotech, Inc. Company Information
  69. 8.12.2 Shanghai Henlius Biotech, Inc. Business Overview
  70. 8.12.3 Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drugs Product Portfolio
  72. 8.12.5 Shanghai Henlius Biotech, Inc. Recent Developments
  73. 8.13 Dizal Pharma
  74. 8.13.1 Dizal Pharma Company Information
  75. 8.13.2 Dizal Pharma Business Overview
  76. 8.13.3 Dizal Pharma First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Dizal Pharma First in Class (FIC) Antibody Drugs Product Portfolio
  78. 8.13.5 Dizal Pharma Recent Developments
  79. 8.14 AstraZeneca
  80. 8.14.1 AstraZeneca Company Information
  81. 8.14.2 AstraZeneca Business Overview
  82. 8.14.3 AstraZeneca First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 AstraZeneca First in Class (FIC) Antibody Drugs Product Portfolio
  84. 8.14.5 AstraZeneca Recent Developments
  85. 8.15 Vertex Pharmaceuticals
  86. 8.15.1 Vertex Pharmaceuticals Company Information
  87. 8.15.2 Vertex Pharmaceuticals Business Overview
  88. 8.15.3 Vertex Pharmaceuticals First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Vertex Pharmaceuticals First in Class (FIC) Antibody Drugs Product Portfolio
  90. 8.15.5 Vertex Pharmaceuticals Recent Developments
  91. 8.16 Truqap
  92. 8.16.1 Truqap Company Information
  93. 8.16.2 Truqap Business Overview
  94. 8.16.3 Truqap First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Truqap First in Class (FIC) Antibody Drugs Product Portfolio
  96. 8.16.5 Truqap Recent Developments
  97. 8.17 Telix
  98. 8.17.1 Telix Company Information
  99. 8.17.2 Telix Business Overview
  100. 8.17.3 Telix First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Telix First in Class (FIC) Antibody Drugs Product Portfolio
  102. 8.17.5 Telix Recent Developments
  103. 8.18 Talvey
  104. 8.18.1 Talvey Company Information
  105. 8.18.2 Talvey Business Overview
  106. 8.18.3 Talvey First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Talvey First in Class (FIC) Antibody Drugs Product Portfolio
  108. 8.18.5 Talvey Recent Developments
  109. 8.19 Skyclary
  110. 8.19.1 Skyclary Company Information
  111. 8.19.2 Skyclary Business Overview
  112. 8.19.3 Skyclary First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Skyclary First in Class (FIC) Antibody Drugs Product Portfolio
  114. 8.19.5 Skyclary Recent Developments
  115. 8.20 Regeneron Pharmaceuticals
  116. 8.20.1 Regeneron Pharmaceuticals Company Information
  117. 8.20.2 Regeneron Pharmaceuticals Business Overview
  118. 8.20.3 Regeneron Pharmaceuticals First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Regeneron Pharmaceuticals First in Class (FIC) Antibody Drugs Product Portfolio
  120. 8.20.5 Regeneron Pharmaceuticals Recent Developments
  121. 8.21 Pumis Biotechnology (BioNTech)
  122. 8.21.1 Pumis Biotechnology (BioNTech) Company Information
  123. 8.21.2 Pumis Biotechnology (BioNTech) Business Overview
  124. 8.21.3 Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drugs Product Portfolio
  126. 8.21.5 Pumis Biotechnology (BioNTech) Recent Developments
  127. 8.22 Ogsiveo
  128. 8.22.1 Ogsiveo Company Information
  129. 8.22.2 Ogsiveo Business Overview
  130. 8.22.3 Ogsiveo First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Ogsiveo First in Class (FIC) Antibody Drugs Product Portfolio
  132. 8.22.5 Ogsiveo Recent Developments
  133. 8.23 Merus
  134. 8.23.1 Merus Company Information
  135. 8.23.2 Merus Business Overview
  136. 8.23.3 Merus First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Merus First in Class (FIC) Antibody Drugs Product Portfolio
  138. 8.23.5 Merus Recent Developments
  139. 8.24 Lytgobi
  140. 8.24.1 Lytgobi Company Information
  141. 8.24.2 Lytgobi Business Overview
  142. 8.24.3 Lytgobi First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Lytgobi First in Class (FIC) Antibody Drugs Product Portfolio
  144. 8.24.5 Lytgobi Recent Developments
  145. 8.25 Litfulo
  146. 8.25.1 Litfulo Company Information
  147. 8.25.2 Litfulo Business Overview
  148. 8.25.3 Litfulo First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Litfulo First in Class (FIC) Antibody Drugs Product Portfolio
  150. 8.25.5 Litfulo Recent Developments
  151. 8.26 Immatics
  152. 8.26.1 Immatics Company Information
  153. 8.26.2 Immatics Business Overview
  154. 8.26.3 Immatics First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  155. 8.26.4 Immatics First in Class (FIC) Antibody Drugs Product Portfolio
  156. 8.26.5 Immatics Recent Developments
  157. 8.27 Fabhalta
  158. 8.27.1 Fabhalta Company Information
  159. 8.27.2 Fabhalta Business Overview
  160. 8.27.3 Fabhalta First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  161. 8.27.4 Fabhalta First in Class (FIC) Antibody Drugs Product Portfolio
  162. 8.27.5 Fabhalta Recent Developments
  163. 8.28 Bicara Therapeutics
  164. 8.28.1 Bicara Therapeutics Company Information
  165. 8.28.2 Bicara Therapeutics Business Overview
  166. 8.28.3 Bicara Therapeutics First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  167. 8.28.4 Bicara Therapeutics First in Class (FIC) Antibody Drugs Product Portfolio
  168. 8.28.5 Bicara Therapeutics Recent Developments
  169. 8.29 Bayer Corporation
  170. 8.29.1 Bayer Corporation Company Information
  171. 8.29.2 Bayer Corporation Business Overview
  172. 8.29.3 Bayer Corporation First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  173. 8.29.4 Bayer Corporation First in Class (FIC) Antibody Drugs Product Portfolio
  174. 8.29.5 Bayer Corporation Recent Developments
  175. 8.30 Arvinas
  176. 8.30.1 Arvinas Company Information
  177. 8.30.2 Arvinas Business Overview
  178. 8.30.3 Arvinas First in Class (FIC) Antibody Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  179. 8.30.4 Arvinas First in Class (FIC) Antibody Drugs Product Portfolio
  180. 8.30.5 Arvinas Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 First in Class (FIC) Antibody Drugs Value Chain Analysis
  2. 9.1.1 First in Class (FIC) Antibody Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 First in Class (FIC) Antibody Drugs Production Mode & Process
  6. 9.2 First in Class (FIC) Antibody Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 First in Class (FIC) Antibody Drugs Distributors
  9. 9.2.3 First in Class (FIC) Antibody Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst